Form 8-K - Current report:
SEC Accession No. 0001213900-24-067143
Filing Date
2024-08-09
Accepted
2024-08-09 16:10:09
Documents
16
Period of Report
2024-08-09
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0210974-8k_inmune.htm   iXBRL 8-K 29921
2 AT-THE-MARKET SALES AGREEMENT, DATED AUGUST 9, 2024, BY AND AMONG INMUNE BIO INC ea021097401ex1-1_inmune.htm EX-1.1 254329
3 OPINION OF SICHENZIA ROSS FERENCE CARMEL LLP ea021097401ex5-1_inmune.htm EX-5.1 14132
7 GRAPHIC ex5-1_001.jpg GRAPHIC 5580
  Complete submission text file 0001213900-24-067143.txt   552413

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE inmb-20240809.xsd EX-101.SCH 3018
5 XBRL LABEL FILE inmb-20240809_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE inmb-20240809_pre.xml EX-101.PRE 22361
18 EXTRACTED XBRL INSTANCE DOCUMENT ea0210974-8k_inmune_htm.xml XML 3793
Mailing Address 225 NE MIZNER BLVD, SUITE 640 BOCA RATON FL 33432
Business Address 225 NE MIZNER BLVD, SUITE 640 BOCA RATON FL 33432 8589643720
Inmune Bio, Inc. (Filer) CIK: 0001711754 (see all company filings)

EIN.: 475205835 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38793 | Film No.: 241192830
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)